{"id":"NCT00462670","sponsor":"Otsuka Pharmaceutical Co., Ltd.","briefTitle":"A Double-blind, Placebo-controlled Study of OPC-41061 in the Treatment of Cardiac Edema (Congestive Heart Failure)","officialTitle":"A Double-blind, Placebo-controlled Study of OPC-41061 in the Treatment of Cardiac Edema (Congestive Heart Failure)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2007-04","primaryCompletion":"2008-10","completion":"2008-10","firstPosted":"2007-04-19","resultsPosted":"2014-02-04","lastUpdate":"2014-02-04"},"enrollment":110,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Edema, Cardiac"],"interventions":[{"type":"DRUG","name":"OPC-41061(Tolvaptan)","otherNames":[]}],"arms":[{"label":"1","type":"PLACEBO_COMPARATOR"},{"label":"2","type":"EXPERIMENTAL"}],"summary":"To evaluate the efficacy and safety of 7-day repeated oral administration of OPC-41061 15 mg or placebo in congestive heart failure (CHF) patients with extracellular volume expansion despite the use of a conventional diuretic.","primaryOutcome":{"measure":"Body Weight (Amount of Change)","timeFrame":"baseline, Day 7 or at the time of final trial drug administration","effectByArm":[{"arm":"Placebo","deltaMin":-0.45,"sd":0.93},{"arm":"OPC-41061 15mg","deltaMin":-1.54,"sd":1.61}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.0001"}]},"eligibility":{"minAge":"20 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":8,"countries":["Japan"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":7,"n":57},"commonTop":["Blood Urea Increased","Constipation","Blood Creatinine Increased","Thirst","Blood Potassium Increased"]}}